BioSpace News Archive

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, today announces submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its IgG/IgM antibody SARS-CoV-2 rapid test detection kit.

Benitec Biopharma announced that in accordance with Australian Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, the shareholder resolution to redomicile Benitec to the USA was passed.

Researchers at The Hebrew University of Jerusalem as well as several Yissum start-up companies are exploring a variety of methods to combat the COVID-19 virus, through investigations into AI drug discovery, biochemical detection tools and diagnostic capabilities.

The country’s many centers of research excellence will now be centrally linked to speed efforts to combat the pandemic

ScitoVation, a solution leader recognized as industry experts in cell-based assays and computational methods announced today the launch of a partnership with BioPredic International, a contract services, research and life sciences tools provider based in France.

InVita Healthcare Technologies (formerly HemaTerra Technologies), a leading software provider for complex medical environments including blood and plasma collection, is offering its Rapid Rollout program to blood product collectors to assist in their time of need

As COVID-19 spreads in the Pacific Northwest, health systems have been met with a severe shortage of tests needed to keep up with demand.

BioInvent International AB (“BioInvent”) (OMXS: BINV) today announces that the Board of Directors has resolved to postpone the annual general meeting until May 28, 2020.

Medi-Immune, Ltd., have revealed ProtectivAir®, a breathing device which has proven effective against viral and bacterial pathogens and is expected to be similarly effective against SARS-CoV-2.

Orphan Technologies, a company dedicated to helping patients control their homocysteine levels, today announced that OT-58 for the treatment of cystathionine beta synthase deficiency homocystinuria has been designated a rare pediatric disease (RPD) by the US Food and Drug Administration (FDA). Under the RPD program, if a new drug application for OT-58 is approved,